Progress on human enterovirus 71 infection and its prevention and treatment

doi:10.3877/cma.j.issn.1674-1358.2019.05.004

Abstract

Abstract:

Hand, foot and mouth disease (HFMD) mainly occurs among children under 5 years old, which broke out many times in the Asia-Pacific region recently. The clinical symptoms of HFMD mainly include fever, anorexia, herpes and other mild symptoms, usually self-limited but a few cases were complicated with serious central nervous system, respiratory, cardiovascular system complications, and even death. Human enterovirus 71 (EV71) is one of the most common pathogens of HFMD, and it is more likely to lead to severe cases, which should be paid great attention. This review summarizes the latest progress of EV71 infection mechanism and vaccine research and development, and to provide some inspiration and basis for the prevention and treatment of HFMD.

Key words: Hand, foot and mouth disease, Enterovirus 71, Vaccine

Yonghong Yan, Shunai Liu, Jun Cheng, Pu Liang. Progress on human enterovirus 71 infection and its prevention and treatment[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(05): 366-369.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2019.05.004

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2019/V13/I05/366

References 40

[1]	Omaña-Cepeda C,Martínez-Valverde A,Sabater- Recolons M, et al. A literature review and case report of hand, foot and mouth disease in an immunocompetent adult[J]. BMC Res Notes,2016,9(1):165.
[2]	Kim BI,Ki H,Park S, et al. Effect of climatic factors on hand, foot, and mouth disease in South Korea, 2010-2013[J]. PLoS One,2016,11(6):e0157500.
[3]	Solomon T,Lewthwaite P,Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71[J]. Lancet Infect Dis,2010,10(11):778-790.
[4]	Ping-Chin C,Shou-Chien C,Kow-Tong C. The current status of the disease caused by enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development[J]. Int J Environ Res Public Health,2016,13(9):890-904.
[5]	Wang SM,Ho TS,Lin HC, et al. Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity[J]. Eur J Clin Microbiol Infect Dis,2012,31(6):1219-1224.
[6]	Lee KY. Enterovirus 71 infection and neurological complications[J]. Korean J Pediatr,2016,59(10):395-401.
[7]	Yang SG,Wu J,Ding C, et al. Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: an observational trend study[J]. Lancet Infect Dis,2017,17(7):716-725.
[8]	Cox JA,Hiscox JA,Solomon T, et al. Immunopathogenesis and virus-host interactions of enterovirus 71 in patients with hand, foot and mouth disease[J]. Front Microbiol,2017,8(11):2249.
[9]	Yi EJ,Shin YJ,Kim JH, et al. Enterovirus 71 infection and vaccines[J]. Clin Exp Vaccine Res,2017,6(1):4-14.
[10]	Tee KK,Lam TT,Chan YF, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene[J]. J Virol,2010,84(7):3339-3350.
[11]	Yamayoshi S,Iizuka S,Yamashita T, et al. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71[J]. J Virol,2012,86(10):5686-5696.
[12]	Nishimura Y,Lee H,Hafenstein S, et al. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction[J]. PLoS Pathog,2013,9(7):e1003511.
[13]	Ren X,Ma L,Liu QW, et al. The molecule of DC-SIGN captures enterovirus 71 and confers dendritic cell-mediated viral trans-infection[J]. Virol J,2014,11(1):47-53.
[14]	Yang SL,Chou YT,Wu CN, et al. Annexin Ⅱ binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity[J]. J Virol,2011,85(22):11809-11820.
[15]	Tan CW,Poh CL,Sam IC, et al. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor[J]. J Virol,2013,87(1):611-620.
[16]	Yang B,Chuang H,Yang KD. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells[J]. Virol J,2009,6(9):141-146.
[17]	Kim YI,Song JH,Kwon BE, et al. Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection[J]. Vaccine,2015,33(48):6604-6610.
[18]	Foo DG,Alonso S,Phoon MC, et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides[J]. Virus Res,2007,125(1):61-68.
[19]	Kim HJ,Son HS,Lee SW, et al. Efficient expression of enterovirus 71 based on virus-like particles vaccine[J]. PLoS One,2019,14(3):e0210477.
[20]	Zhao H,Li HY,Han JF, et al. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and Coxsackievirus A16 in mice[J]. Sci Rep,2015,5(1):7878-7885.
[21]	Ye X,Ku Z,Liu Q, et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms[J]. J Virol,2014,88(1):72-81.
[22]	Tung WS,Bakar SA,Sekawi Z, et al. DNA vaccine constructs against enterovirus 71 elicit immune response in mice[J]. Genet Vaccines Ther,2007,5(4):6-18.
[23]	Chiu CH,Chu C,He CC, et al. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71[J]. Microbes Infect,2006,8(7):1671-1678.
[24]	Tsou YL,Lin YW,Shao HY, et al. Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease[J]. PLoS Negl Trop Dis,2015,9(4):e0003692.
[25]	Chen HF,Chang MH,Chiang BL, et al. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71[J]. Vaccine,2006,24(15):2944-2951.
[26]	Arita M,Nagata N,Iwata N, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys[J]. J Virol,2007,81(17):9386-9395.
[27]	Meng T,Kwang J. Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice[J]. J Virol,2014,88(10):5803-5815.
[28]	Zhu FC,Meng FY,Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet,2013,381(9882):2024-2032.
[29]	Zhu F,Xu W,Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China[J]. N Engl J Med,2014,370(9):818-828.
[30]	Li R,Liu L,Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children[J]. N Engl J Med,2014,370(9):829-837.
[31]	Zhang G,Zhou F,Gu B, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection[J]. Arch Virol,2012,157(4):669-679.
[32]	Weng TY,Chen LC,Shyu HW, et al. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells[J]. Antiviral Res,2005,67(1):31-37.
[33]	Lu G,Qi J,Chen Z, et al. Enterovirus 71 and Coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design[J]. J Virol,2011,85(19):10319-10331.
[34]	Kishimoto C,Crumpacker CS,Abelmann WH. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets[J]. J Am Coll Cardiol,1988,12(5):1334-1341.
[35]	Chen TC,Chang HY,Lin PF, et al. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71[J]. Antimicrob Agents Chemother,2009,53(7):2740-2747.
[36]	Arita M,Takebe Y,Wakita T, et al. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection[J]. J Gen Virol,2010,91(Pt 11):2734-2744.
[37]	Tsai FJ,Lin CW,Lai CC, et al. Kaempferol inhibits enterovirus 71 replication and internal ribosome entry site (IRES) activity through FUBP and HNRP proteins[J]. Food Chem,2011,128(2):312-322.
[38]	Tan EL,Tan TM,Tak Kwong Chow V, et al. Inhibition of enterovirus 71 in virus-infected mice by RNA interference[J]. Mol Ther,2007,15(11):1931-1938.
[39]	Ng Q,He F,Kwang J. Recent progress towards novel EV71 anti-therapeutics and vaccines[J]. Viruses,2015,7(12):6441-6457.
[40]	Kiener TK,Jia Q,Meng T, et al. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein[J]. PLoS Negl Trop Dis,2014,8(5):e2895.

Please choose a citation manager

Content to export